# Innovacell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovacell-2

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.innovacell.co.jp
- Latest round: Series D (Aug 21, 2025)
- Investors on record: 7

## About

Founded in 2021 and based in Tokyo, Japan, innovacell Inc., d.b.a. innovacell, specializes in regenerative medicine. In February 2026, Innovacell raised JPY 12.3 billion in an IPO, selling 9,125,300 shares at JPY 1350 per share at the Growth Market. The listing value Innovacell at JPY 56.3 billion.
The company specializes in the development and commercialization of regenerative medicine products utilizing human cells. The firm’s primary focus is on creating cell-based therapies aimed at addressing urinary and fecal incontinence, with three distinct autologous cell treatment pipelines currently under development. These therapies are designed to improve the quality of life for patients suffering from these conditions by enhancing their ability to manage incontinence. Innovacell’s products are developed through research and exploration of human cell applications across various global markets.

Innovacell generates revenue through the commercialization of its regenerative medicine products, particularly focusing on partnerships with healthcare providers and institutions. The company structures its transactions through collaborations in the healthcare sector, involving business-to-business agreements with hospitals, clinics, and medical professionals who utilize their therapies.

## Funding rounds

- Series D, Aug 21, 2025 — SBI Investment, MIRAIDOOR, UntroD Capital, Happiness Capital, Alfresa Corporation, Rheos Capital Partners, FUNDINNO

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series D
- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Series D
- UntroD Capital — Series D
- Happiness Capital (https://capitalatlas.ai/funds/happiness-capital) — Series D
- Alfresa Corporation — Series D
- Rheos Capital Partners (https://capitalatlas.ai/funds/rheos-capital-partners) — Series D
- FUNDINNO — Series D